The basal cell carcinoma market is anticipated to experience a positive shift due to the better uptake of existing drugs, the expected market launch of new therapies such as Remetinostat (Medvir), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), and others, and increased awareness.
LAS VEGAS, Dec. 4, 2025 /PRNewswire/ -- DelveInsight's Basal Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, basal cell carcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Basal Cell Carcinoma Market Summary
- The market size for basal cell carcinoma in the leading markets is expected to grow significantly by 2034.
- The United States accounted for the highest basal cell carcinoma treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
- BCC is the most common form of skin cancer. An estimated 3.6 million cases of BCC are diagnosed in the US each year.
- Leading basal cell carcinoma companies developing emerging therapies, such as Medvir, Sirnaomics, Stamford Pharmaceuticals, Lytix Biopharma, Verrica Pharmaceuticals, and others, are developing new therapy for basal cell carcinoma that can be available in the basal cell carcinoma market in the coming years.
- The promising basal cell carcinoma therapies in clinical trials include Remetinostat, STP705, SP-002, LTX-315/VP-315, and others.
Discover the basal cell carcinoma new treatment @ New Treatments for Basal Cell Carcinoma
Key Factors Driving the Growth of the Basal Cell Carcinoma Market
Rising Incidence and Aging Population
The global incidence of basal cell carcinoma is increasing due to prolonged exposure to ultraviolet (UV) radiation, genetic predispositions, and an aging population that is more susceptible to skin cancers. As people live longer and spend more time outdoors, the number of diagnosed cases continues to rise, fueling demand for effective treatments.
Technological Advancements and Treatment Innovations
Recent years have seen significant progress in BCC treatment modalities, including targeted therapies (such as hedgehog pathway inhibitors like vismodegib and sonidegib), immunotherapies, and personalized medicine approaches. Minimally invasive options, such as intralesional injections and topical treatments, are gaining popularity due to their reduced side effects and improved patient outcomes. The integration of artificial intelligence (AI) and digital health solutions is also enhancing early diagnosis and treatment planning.
Launch of Emerging BCC Drugs
The expected launch of therapies such as Remetinostat (Medvir), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), and others will change the dynamics of the BCC market.
Basal Cell Carcinoma Market Analysis
Current treatment options for basal cell carcinoma include topical medications such as 5-fluorouracil and imiquimod, photodynamic therapy using methyl aminolevulinate cream, tazarotene, hedgehog pathway inhibitors (HHPIs), and the PD-1 inhibitor cemiplimab.
The U.S. FDA has approved several therapies for advanced BCC, including cemiplimab (LIBTAYO, by Regeneron Pharmaceuticals and Sanofi), vismodegib (ERIVEDGE, by Genentech), and sonidegib (ODOMZO, by Novartis), among others.
Notable emerging players developing novel BCC treatments include Medvir (remetinostat), Sirnaomics (STP705), Stamford Pharmaceuticals (SP-002), and Lytix Biopharma/Verrica Pharmaceuticals (LTX-315/VP-315), all contributing to a promising pipeline of future therapeutic options.
To know more about basal cell carcinoma treatment options, visit @ Approved Basal Cell Carcinoma Drugs
Basal Cell Carcinoma Competitive Landscape
Some of the BCC drugs in clinical trials include Remetinostat (Medvir), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), and others.
Lytix Biopharma/Verrica Pharmaceuticals' LTX-315 is an oncolytic peptide designed for direct injection into tumors. It destroys cancer cells while activating the immune system to enhance antitumor activity. Preclinical data demonstrate its ability to suppress tumor growth, trigger regression, and establish long-term immune protection. Verrica Pharmaceuticals has licensed LTX-315, a first-in-class oncolytic peptide immunotherapy, from Lytix Biopharma AS for use in dermatologic oncology. The U.S. patents for LTX-315 are expected to expire between 2032 and 2045.
Stamford Pharmaceuticals' SP-002 is an adenovirus-based biologic engineered to express Interferon-g, an immunostimulatory protein with anticancer properties. Stamford Pharmaceuticals holds an exclusive global license to develop SP-002 (formerly TG1042) from Transgene, a French biopharmaceutical company. A Phase IIb trial for locally advanced basal cell carcinoma (laBCC) is currently underway, with Phase III studies in BCC expected to commence in late 2025 or early 2026.
Sirnaomics' STP705 is a dual inhibitor targeting TGF-ß1 and COX-2, two key molecular drivers in oncology and fibrosis. By downregulating these genes, STP705 aims to suppress tumor growth and potentially offer a non-surgical treatment option for BCC. Recent Phase II results have shown remarkable efficacy with no drug-related or serious adverse events, reinforcing the candidate's strong potential in treating non-melanoma skin cancers and other indications.
The anticipated launch of these emerging therapies are poised to transform the basal cell carcinoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the basal cell carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for basal cell carcinoma @ Basal Cell Carcinoma Clinical Trials
What is Basal Cell Carcinoma?
Basal cell carcinoma (BCC), formerly known as basal cell epithelioma, is the most common form of skin cancer. It generally grows slowly, and metastasis occurs only in rare cases. BCC usually stays confined to the skin, and surgical interventions are the primary and most effective treatment approaches. Common procedures include surgical excision, electrodesiccation with curettage, and Mohs micrographic surgery, all offering high cure rates depending on the tumor's type and site.
Basal Cell Carcinoma Epidemiology Segmentation
The basal cell carcinoma epidemiology section provides insights into the historical and current basal cell carcinoma patient pool and forecasted trends for the leading markets. BCC is more common in the male population compared to females, attributed to greater sun exposure among men.
The basal cell carcinoma market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
- Total Incident Cases of Non-Melanoma Skin Cancer
- Total Incident Cases of BCC
- Subtype-specific Incident Cases of BCC
- Stage-specific Incident Cases of BCC
- Line-wise Treated Cases of BCC
Basal Cell Carcinoma Market Report Metrics | Details |
Study Period | 2020-2034 |
Basal Cell Carcinoma Market Report Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
Basal Cell Carcinoma Epidemiology Segmentation | Total Incident Cases of Non-Melanoma Skin Cancer, Total Incident Cases of BCC, Subtype-specific Incident Cases of BCC, Stage-specific Incident Cases of BCC, and Line-wise Treated Cases of BCC |
Key Basal Cell Carcinoma Companies | Medvir, Sirnaomics, Stamford Pharmaceuticals, Lytix Biopharma, Verrica Pharmaceuticals, Regeneron, Sanofi, Novartis, Genentech, and others |
Key Basal Cell Carcinoma Therapies | Remetinostat, STP705, SP-002, LTX-315/VP-315, LIBTAYO, ODOMZO, ERIVEDGE, and others |
Scope of the Basal Cell Carcinoma Market Report
- Therapeutic Assessment: Basal Cell Carcinoma current marketed and emerging therapies
- Basal Cell Carcinoma Market Dynamics: Key Market Forecast Assumptions of Emerging Basal Cell Carcinoma Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Basal Cell Carcinoma Market Access and Reimbursement
Download the report to understand which factors are driving basal cell carcinoma therapeutics market trends @ Basal Cell Carcinoma Market Trends
Table of Contents
1 | Basal Cell Carcinoma Market Key Insights |
2 | Basal Cell Carcinoma Market Report Introduction |
3 | Executive Summary of BCC |
4 | Key Events |
5 | BCC Epidemiology and Market Forecast Methodology |
6 | BCC Market Overview at a Glance |
6.1 | Clinical Landscape Analysis (by Phase, RoA, and Molecule Type) |
6.2 | Market Share (%) Distribution of BCC by Therapies in 2024 |
6.3 | Market Share (%) Distribution of BCC by Therapies in 2034 |
7 | Disease Background and Overview: BCC |
7.1 | Introduction |
7.2 | Basal Cell Carcinoma Signs and Symptoms |
7.3 | Basal Cell Carcinoma Causes |
7.4 | Basal Cell Carcinoma Diagnosis |
8 | Basal Cell Carcinoma Treatment and Management |
8.1 | Treatment Guidelines and Recommendations (NCCN, ESMO) |
9 | Epidemiology and Patient Population of BCC in the 7MM |
9.1 | Key Findings |
9.2 | Assumptions and Rationale |
9.3 | Total Incident Cases of BCC in the 7MM |
9.4 | The United States |
9.4.1 | Total Incident Cases of Non-Melanoma Skin Cancer in the United States |
9.4.2 | Total Incident Cases of BCC in the United States |
9.4.3 | Subtype-specific Incident Cases of BCC in the United States |
9.4.2 | Stage-specific Incident Cases of BCC in the United States |
9.4.5 | Line-wise Treated Cases of BCC in the United States |
9.5 | EU4 and the UK |
9.6 | Japan |
10 | Basal Cell Carcinoma Patient Journey |
11 | Marketed Basal Cell Carcinoma Therapies |
11.1 | Key Competitors |
11.2 | Cemiplimab (LIBTAYO): Regeneron and Sanofi |
11.2.1 | Product Description |
11.2.2 | Regulatory Milestones |
11.2.3 | Other Developmental Activities |
11.2.4 | Summary of Pivotal Trials |
11.2.5 | Clinical Development |
11.2.5.1 | Clinical Trials Information |
11.2.6 | Safety and Efficacy |
11.2.7 | Analyst Views |
11.3 | Sonidegib (ODOMZO): Novartis |
List to be continued in the report… | |
12 | Emerging Basal Cell Carcinoma Therapies |
12.1 | Key Competitors |
12.2 | LTX-315/VP-315: Lytix Biopharma/Verrica Pharmaceuticals |
12.2.1 | Product Description |
12.2.2 | Other Developmental Activities |
12.2.3 | Clinical Development |
12.2.3.1 | Clinical Trials Information |
12.2.4 | Safety and Efficacy |
12.2.5 | Analyst Views |
12.3 | SP-002: Stamford Pharmaceuticals |
List to be continued in the report… | |
13 | BCC Market: 7MM Analysis |
13.1 | Key Findings |
13.2 | Key Basal Cell Carcinoma Market Forecast Assumptions |
13.3 | Basal Cell Carcinoma Market Outlook |
13.4 | Conjoint Analysis |
13.5 | Total Market Size of BCC in the 7MM |
13.6 | Total Market Size of BCC by Therapies in the 7MM |
13.7 | The United States Basal Cell Carcinoma Market Size |
13.7.1 | Total Market Size of BCC in the United States |
13.7.2. | Market Size of BCC by Therapies in the United States |
13.8 | EU4 and the UK Basal Cell Carcinoma Market Size |
13.9 | Japan Basal Cell Carcinoma Market Size |
14 | KOL Views on Basal Cell Carcinoma |
15 | Basal Cell Carcinoma Market SWOT Analysis |
16 | Basal Cell Carcinoma Market Unmet Needs |
17 | Basal Cell Carcinoma Market Access and Reimbursement |
17.1 | The United States |
17.2 | In EU4 and the UK |
17.3 | Japan |
17.4 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
17.5 | Market Access and Reimbursement of BCC |
18 | Bibliography |
19 | Basal Cell Carcinoma Market Report Methodology |
Related Reports
Basal Cell Carcinoma Clinical Trial Analysis
Basal Cell Carcinoma Pipeline Insight - 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key BCC companies, including PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, among others.
Nevoid Basal Cell Carcinoma Syndrome Market
Nevoid Basal Cell Carcinoma Syndrome Market Insights, Epidemiology, and Market Forecast - 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nevoid basal cell carcinoma syndrome companies, including Medicus Pharma Ltd., Sol-Gel Technologies, Jazz Pharmaceuticals, Ono Pharmaceuticals, Bristol Myers Squibb, Inhibitor Therapeutics, Genentech, Feldan Therapeutics Inc., Kintara Therapeutics Inc., Mayne Pharma Group Ltd., Palvella Therapeutics LLC, PellePharm Inc., among others.
Nevoid Basal Cell Carcinoma Syndrome Pipeline
Nevoid Basal Cell Carcinoma Syndrome Pipeline Insight - 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key BCC companies, including Medicus Pharma Ltd., Sol-Gel Technologies, Jazz Pharmaceuticals, Ono Pharmaceuticals, Bristol Myers Squibb, Inhibitor Therapeutics, Genentech, Feldan Therapeutics Inc., Kintara Therapeutics Inc., Mayne Pharma Group Ltd., Palvella Therapeutics LLC, PellePharm Inc., among others.
Cutaneous Squamous Cell Carcinoma Market
Cutaneous Squamous Cell Carcinoma Market Insight, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key cutaneous squamous cell carcinoma companies, including Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo - https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/basal-cell-carcinoma-market-poised-for-steady-growth-throughout-forecast-period-20252034-driven-by-novel-drug-approvals-and-expanding-patient-pool--delveinsight-302627765.html
